Denali Therapeutics (DNLI) Depreciation and Depletion (2017 - 2018)

Denali Therapeutics (DNLI) reported Depreciation and Depletion of $2.3 million for Q3 2018, up 199.1% year-over-year from $778000.0 in Q3 2017, and up 25.44% on a QoQ basis from $1.9 million in Q2 2018.

Denali Therapeutics (DNLI) has 2 years of Depreciation and Depletion data on file, last reported at $2.3 million in Q3 2018.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Depreciation and Depletion (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 1,395.22
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Denali Therapeutics 3.82 Bn 3.82 Bn - -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2018 2.33 Mn
Sep 30, 2018 2.33 Mn
Jun 30, 2018 1.86 Mn
Jun 30, 2018 1.86 Mn
Mar 31, 2018 854,000.00
Mar 31, 2018 854,000.00
Sep 30, 2017 778,000.00
Sep 30, 2017 778,000.00
Jun 30, 2017 766,000.00
Jun 30, 2017 766,000.00
Mar 31, 2017 731,000.00
Mar 31, 2017 731,000.00